Top

Published in:

01-11-2020 | Amphotericin B | Topic Paper

Candida urinary tract infections in adults

Authors: Zekaver Odabasi, Ali Mert

Published in: World Journal of Urology | Issue 11/2020

Abstract

Candiduria is commonly seen in hospitalized patients and most of the patients are asymptomatic, but it may be due to cystitis, pyelonephritis, prostatitis, epididymo-orchitis or disseminated candidiasis. Major risk factors are diabetes mellitus, indwelling urinary catheters, use of broad-spectrum antibiotics, urinary obstruction, and admission to intensive care units. Candida urinary tract infections can be caused by hematogenous spread following candidemia, or retrograde route via the urethra. The presence of Candida species in urine in asymptomatic patients does not warrant antifungal therapy except neutropenic patients, very low-birth-weight infants and patients undergoing urologic procedures. Fluconazole is the treatment of choice for symptomatic infections, it achieves high urinary levels. The other azole antifungals and echinocandins do not reach sufficient urine levels. Amphotericin B deoxycholate is the alternative antifungal agent if fluconazole can not be used because of resistance, allergy or failure.

Colodner R, Nuri Y, Chazan B et al (2008) Community-acquired and hospital-acquired candiduria: comparison of prevalence and clinical characteristics. Eur J Clin Microbiol Infect Dis 27:301–305

Alvarez-Lerma F, Nolla-Salas J, León C et al (2003) Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med 29:1069–1076

Bouza E, San Juan R, Muñoz P et al (2001) A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clin Microbiol Infect 7:532–542

Padawer D, Pastukh N, Nitzan O et al (2015) Catheter-associated candiduria: risk factors, medical interventions, and antifungal susceptibility. Am J Infect Control 43:e19–e22

Aubron C, Suzuki S, Glassford NJ et al (2015) The epidemiology of bacteriuria and candiduria in critically ill patients. Epidemiol Infect 143:653–662

Delgado J, Calvo N, Gomis A et al (2010) Candiduria in renal transplant recipients: incidence, clinical repercussion, and treatment indication. Transplant Proc 42:2944–2946

Denis B, Chopin D, Piron P et al (2018) Candiduria in kidney transplant recipients: is antifungal therapy useful? Mycoses 61:298–304

Goetz LL, Howard M, Cipher D et al (2010) Occurrence of candiduria in a population of chronically catheterized patients with spinal cord injury. Spinal Cord 48:51–54

Esmailzadeh A, Zarrinfar H, Fata A et al (2018) High prevalence of candiduria due to non-albicans Candida species among diabetic patients: a matter of concern? J Clin Lab Anal 32:e22343

10.

Kauffman CA, Vazquez JA, Sobel JD et al (2000) Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 30:14–18

11.

Bougnoux ME, Kac G, Aegerter P et al (2008) Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 34:292–299

12.

Georgiadou SP, Tarrand J, Sipsas NV et al (2013) Candiduria in haematologic malignancy patients without a urinary catheter: nothing more than a frailty marker? Mycoses 56:311–314

13.

Drogari-Apiranthitou M, Anyfantis I, Galani I et al (2017) Association between candiduria and candidemia: a clinical and molecular analysis of cases. Mycopathologia 182:1045–1052

14.

Binelli CA, Moretti ML, Assis RS et al (2006) Investigation of the possible association between nosocomial candiduria and candidaemia. Clin Microbiol Infect 12:538–543

15.

Safdar N, Slattery WR, Knasinski V et al (2005) Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis 40:1413–1421

16.

Blumberg HM, Jarvis WR, Soucie JM et al (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33:177–186

17.

Simpson C, Blitz S, Shafran SD (2004) The effect of current management on morbidity and mortality in hospitalised adults with funguria. J Infect 49:248–252

18.

Wang K, Hsueh K, Kronen R et al (2019) Creation and assessment of a clinical predictive model for candidaemia in patients with candiduria. Mycoses 62:554–561

19.

Alfouzan WA, Dhar R (2017) Candiduria: evidence-based approach to management, are we there yet? J Mycol Med 27:293–302

20.

Kauffman CA (2014) Diagnosis and management of fungal urinary tract infection. Infect Dis Clin North Am 28:61–74

21.

Pappas PG, Kauffman CA, Andes DR et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1–50

22.

Spivak ES, Hanson KE (2018) Candida auris: an emerging fungal pathogen. J Clin Microbiol. https://doi.org/10.1128/JCM.01588-17CrossRef

23.

Sobel JD, Fisher JF, Kauffman CA et al (2011) Candida urinary tract infections—epidemiology. Clin Infect Dis 52(Suppl 6):S433–S436

24.

Fisher JF, Kavanagh K, Sobel JD et al (2011) Candida urinary tract infection: pathogenesis. Clin Infect Dis 52(Suppl 6):S437–S451

25.

Lewis SS, Knelson LP, Moehring RW et al (2013) Comparison of non-intensive care unit (ICU) versus ICU rates of catheter-associated urinary tract infection in community hospitals. Infect Control Hosp Epidemiol 34:744–747

26.

Thomas L, Tracy CR (2015) Treatment of fungal urinary tract infection. Urol Clin North Am 42:473–483

27.

Sobel JD, Vazquez JA (1999) Fungal infections of the urinary tract. World J Urol 17:410–414

28.

Kontoyiannis DP, Lionakis MS, Lewis RE et al (2005) Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191:1350–1360

29.

Pemán J, Ruiz-Gaitán A (2018) Candidemia from urinary tract source: the challenge of candiduria. Hosp Pract 46:243–245

30.

Gaisne R, Jeddi F, Morio F et al (2018) Candida utilis fungaemia following endoscopic intervention on ureteral stent in a kidney transplant recipient: case report and a review of the literature. Mycoses 61:594–599

31.

Gross M, Winkler H, Pitlik S et al (1998) Unexpected candidemia complicating ureteroscopy and urinary stenting. Eur J Clin Microbiol Infect Dis 17:583–586

32.

Ang BS, Telenti A, King B et al (1993) Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis 17:662–666

33.

Beck SM, Finley DS, Deane LA (2008) Fungal urosepsis after ureteroscopy in cirrhotic patients: a word of caution. Urology 72:291–293

34.

Fisher J, Mayhall G, Duma R et al (1979) Fungus balls of the urinary tract. South Med J 72(1281–1284):1287

35.

Tan WP, Turba UC, Deane LA (2017) Renal fungus ball: a challenging clinical problem. Urologia 84:113–115

36.

Praz V, Burruni R, Meid F et al (2014) Fungus ball in the urinary tract: a rare entity. Can Urol Assoc J 8:E118–E120

37.

Kauffman CA, Fisher JF, Sobel JD et al (2011) Candida urinary tract infections–diagnosis. Clin Infect Dis 52(Suppl 6):S452–S456

38.

Jenkin GA, Choo M, Hosking P et al (1998) Candidal epididymo-orchitis: case report and review. Clin Infect Dis 26:942–945

39.

Wise GJ, Shteynshlyuger A (2006) How to diagnose and treat fungal infections in chronic prostatitis. Curr Urol Rep 7:320–328

40.

Sobel JD, Kauffman CA, McKinsey D et al (2000) Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 30:19–24

41.

Fisher JF (2011) Candida urinary tract infections—epidemiology, pathogenesis, diagnosis, and treatment: executive summary. Clin Infect Dis 52(Suppl 6):S429–S432

42.

Magri V, Cariani L, Bonamore R et al (2005) Microscopic and microbiological findings for evaluation of chronic prostatitis. Arch Ital Urol Androl 77:135–138

43.

Di Paola G, Mogorovich A, Fiorini G et al (2011) Candida bezoars with urinary tract obstruction in two women without immunocompromising conditions. Sci World J 11:1168–1172

44.

Fisher JF, Sobel JD, Kauffman CA et al (2011) Candida urinary tract infections—treatment. Clin Infect Dis 52(Suppl 6):S457–S466

45.

Jacobs DM, Dilworth TJ, Beyda ND et al (2018) Overtreatment of asymptomatic candiduria among hospitalized patients: a multi-institutional study. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01464-17CrossRef

46.

Leon C, Ruiz-Santana S, Saavedra P et al (2009) Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37:1624–1633

47.

Leon C, Ruiz-Santana S, Saavedra P et al (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730–737

48.

Pittet D, Monod M, Suter PM et al (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751–758

49.

Malani AN, Kauffman CA (2007) Candida urinary tract infections: treatment options. Expert Rev Anti Infect Ther 5:277–284

50.

Miceli MH, Kauffman CA (2015) Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 61:1558–1565

51.

Felton T, Troke PF, Hope WW (2014) Tissue penetration of antifungal agents. Clin Microbiol Rev 27:68–88

52.

Gabardi S, Martin S, Sura M et al (2016) Micafungin treatment and eradication of candiduria among hospitalized patients. Int Urol Nephrol 48:1881–1885

53.

Grau S, Luque S, Echeverria-Esnal D et al (2016) Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp. Int J Antimicrob Agents 48:212–214

54.

Sobel JD, Bradshaw SK, Lipka CJ et al (2007) Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 44:e46–e49

55.

Drew RH, Arthur RR, Perfect JR (2005) Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis 40:1465–1470

56.

Tuon FF, Amato VS, Penteado Filho SR (2009) Bladder irrigation with amphotericin B and fungal urinary tract infection–systematic review with meta-analysis. Int J Infect Dis 13:701–706

57.

Chung BH, Chang SY, Kim SI et al (2001) Successfully treated renal fungal ball with continuous irrigation of fluconazole. J Urol 166:1835–1836

58.

Sobel JD (2007) Vulvovaginal candidosis. Lancet 369:1961–1971

59.

Cottreau JM, Barr VO (2016) A review of antiviral and antifungal use and safety during pregnancy. Pharmacotherapy 36:668–678

Title: Candida urinary tract infections in adults
Authors: Zekaver Odabasi
Ali Mert
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Keywords: Amphotericin B
Candidiasis
Prostatitis
Orchitis
Candidiasis
Fluconazole
Pyelonephritis
Cystitis
Flucytosine
Cystitis
Urinary Tract Infection
Pyelonephritis
Published in: World Journal of Urology / Issue 11/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02991-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Candida urinary tract infections in adults

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2020

Current perspectives on urolithiasis management in China

TUR-P phantom for resident surgical training: food-based design as a human mimicking model of the prostate

Paravertebral block for percutaneous nephrolithotomy: a prospective, randomized, double-blind placebo-controlled study

Traumatic spinal cord injury confers bladder cancer risk to patients managed without permanent urinary catheterization: lessons from a comparison of clinical data with the national database

Epidemiology of urological infections: a global burden

Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines